Medical Corporation Heishinkai OPHAC Hospital
Osaka, Japan
NCT Number: NCT05905653
To evaluate the safety and plasma pharmacokinetics of STN1012600 ophthalmic solution 0.002% (1 drop once daily for 7 days) in healthy adult male subjects.
Looking for future studies?
Notify Me18 year–35 year
Male
Interventional
Phase 1
Osaka, Japan
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 drop STN1012600 ophthalmic solution 0.002% once daily for 7 days
Time frame: 1 week, Day 1 and Day 7
Calculate plasma pharmacokinetic parameters and study pharmacokinetics.
Time frame: 1 week, Day 1 and Day 7
Calculate plasma pharmacokinetic parameters and study pharmacokinetics.
Santen Pharmaceutical Co., Ltd.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07146711
Healthy Adult Males Volunteers
Yerevan, Akunk Region, Armenia
View Trial Details